Cited 8 times in
Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2022-09-14T01:19:09Z | - |
dc.date.available | 2022-09-14T01:19:09Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190394 | - |
dc.description.abstract | Neuroendocrine tumors (NETs) are a group of malignancies arising from neuroendocrine cells and frequently originate in the gastrointestinal tract and pancreas. Although curative resection is the main treatment for localized disease, systemic therapy is needed for relapsed or metastatic/unresectable gastroenteropancreatic NETs (GEP-NETs). Although there are several NET treatment guidelines from various countries, the geographical discrepancies between patient clinical characteristics, the regulatory approval status for therapeutic agents, and medical practices necessitate specific guidelines for Korean patients. We here provide a consensus review of the diagnosis, staging and systemic treatment of Korean GEP-NET patients. Systemic therapy options and the current Korean expert consensus on these treatments, including somatostatin analogs, targeted therapies such as everolimus and sunitinib, peptide receptor radionuclide treatments, and cytotoxic chemotherapies are addressed. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Official journal of Korean Cancer Association | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intestinal Neoplasms / mortality | - |
dc.subject.MESH | Intestinal Neoplasms / therapy* | - |
dc.subject.MESH | Neuroendocrine Tumors / mortality | - |
dc.subject.MESH | Neuroendocrine Tumors / therapy* | - |
dc.subject.MESH | Pancreatic Neoplasms / mortality | - |
dc.subject.MESH | Pancreatic Neoplasms / therapy* | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Stomach Neoplasms / mortality | - |
dc.subject.MESH | Stomach Neoplasms / therapy* | - |
dc.title | Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Changhoon Yoo | - |
dc.contributor.googleauthor | Chung Ryul Oh | - |
dc.contributor.googleauthor | Seung-Tae Kim | - |
dc.contributor.googleauthor | Woo Kyun Bae | - |
dc.contributor.googleauthor | Hye-Jin Choi | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | Myung-Ah Lee | - |
dc.contributor.googleauthor | Baek-Yeol Ryoo | - |
dc.identifier.doi | 10.4143/crt.2020.1233 | - |
dc.contributor.localId | A04219 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 33421978 | - |
dc.subject.keyword | Capecitabine | - |
dc.subject.keyword | Everolimus | - |
dc.subject.keyword | Lanreotide | - |
dc.subject.keyword | Neuroendocrine tumor | - |
dc.subject.keyword | Octreotide | - |
dc.subject.keyword | Peptide receptor radionuclide therapy | - |
dc.subject.keyword | Sunitinib | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | 최혜진 | - |
dc.citation.volume | 53 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 291 | - |
dc.citation.endPage | 300 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.53(2) : 291-300, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.